JP2016536012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536012A5 JP2016536012A5 JP2016549206A JP2016549206A JP2016536012A5 JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5
- Authority
- JP
- Japan
- Prior art keywords
- pkal
- inhibitor
- assay
- subject
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 13
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 11
- 102100011311 KNG1 Human genes 0.000 claims 11
- 210000002381 Plasma Anatomy 0.000 claims 8
- 238000004166 bioassay Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000012190 activator Substances 0.000 claims 5
- 239000000758 substrate Substances 0.000 claims 5
- 102000003827 Plasma kallikrein Human genes 0.000 claims 4
- 108090000113 Plasma kallikrein Proteins 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 238000001262 western blot Methods 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 230000001809 detectable Effects 0.000 claims 2
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 238000010228 ex vivo assay Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000000678 plasma activation Methods 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (23)
- 対象から得た血漿試料を血漿カリクレイン(pKal)系の活性化剤と共にインキュベートすること、
前記インキュベーションの前および後の血漿試料において、インタクト高分子量キニノーゲン(HMWK)、切断型HMWK、もしくはその両方のレベルを測定すること、および
活性化後の試料中のインタクトHMWKの低減を決定すること
を含むエクスビボ活性化方法。 - 対象における血漿活性化を評価する方法であって、
対象からの血漿試料を提供すること、および
前記血漿試料において切断型HMWKのレベルを測定すること
を含む、方法。 - 試料中の血漿カリクレイン(pKal)活性を決定するためのエクスビボアッセイであって、
pKal基質の存在下で前記試料をpKal系活性化剤とインキュベートすること、および
前記基質の切断速度に基づいてpKalの活性を測定すること
を含むアッセイ。 - インタクトHMWKおよび切断型HMWKのレベルがウェスタンブロット解析によって測定される、請求項1又は2に記載の方法。
- 前記ウェスタンブロット解析がProtein Simpleウェスタンブロット解析である、請求項4に記載の方法。
- 前記活性化剤が第XIIa因子である、請求項1又は3に記載の方法。
- 前記血漿試料および活性化剤がpKal阻害剤候補の存在下でインキュベートされ、前記方法は血漿カリクレインに対するpKal阻害剤候補の活性を評価することをさらに含む、請求項1又は3に記載の方法。
- 前記対象が、pKal関連疾患を有するかもしくはその危険性があるかを評価することをさらに含み、既定の値と比較して切断型HMWKのレベルが増加するか、既定の値と比較してpKal活性が増加すれば、前記対象が前記疾患を有するかその危険性があることを示す、請求項1〜3のいずれか1項に記載の方法。
- 前記疾患がHAEである、請求項8に記載の方法。
- 前記対象がpKal関連疾患を有するヒト患者であり、該疾患の治療が行われており、そして前記血漿試料が、前記治療の過程の後もしくは前記治療の過程の最中に得られる、請求項1〜3のいずれか1項に記載の方法。
- 前記治療の有効性を評価することをさらに含み、前記治療前と比較して切断型HMWKのレベルが低減するか、もしくは前記治療の最中にわたって切断型HMWKのレベルが低減すれば、前記治療が有効であることを示す、請求項10に記載の方法。
- 前記患者がHAEを有し、かつpKal阻害剤によって治療される、請求項10に記載の方法。
- 前記pKal阻害剤がDX2930である、請求項12に記載の方法。
- 前記対象が、血漿カリクレイン(pKal)系に関連する疾患を有するかもしくはそれを有する疑いのある、請求項1又は2に記載の方法。
- 前記対象がpKal阻害剤によって治療される、請求項14に記載の方法。
- 前記pKal阻害剤の有効性を評価することをさらに含み、前記治療前と比較して切断型HMWKのレベルが低減すれば、前記pKal阻害剤が有効であることを示す、請求項15に記載の方法。
- 前記試料が対象からの血漿試料である、請求項3に記載の方法。
- 前記基質がpKalによる切断の後に検出可能なシグナルを遊離できる標識に結合し、そして基質の切断速度が、検出可能なシグナルの大きさに基づいて決定される、請求項17に記載のアッセイ。
- 前記血漿試料が、活性化剤、pKal基質、およびpKal阻害剤候補と共にインキュベートされる、請求項3、17、及び18のいずれか1項に記載のアッセイ。
- 前記pKal阻害剤候補のpKalに対する阻害活性を評価することをさらに含み、前記pKal阻害剤候補の非存在下でのpKal活性のレベルと比較して、前記pKal阻害剤候補の存在下でのpKal活性のレベルが低減すれば、前記阻害剤候補が有効であることを示す、請求項19に記載のアッセイ。
- 前記pKal阻害剤がpKalに結合する抗体である、請求項20に記載のアッセイ。
- 前記抗体がDX−2930である、請求項21に記載のアッセイ。
- 前記アッセイがマイクロプレート中で実施される、請求項3、17、および18のいずれか1項に記載のアッセイ。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361893505P | 2013-10-21 | 2013-10-21 | |
US61/893,505 | 2013-10-21 | ||
US201461939837P | 2014-02-14 | 2014-02-14 | |
US61/939,837 | 2014-02-14 | ||
PCT/US2014/061247 WO2015061183A1 (en) | 2013-10-21 | 2014-10-17 | Assays for determining plasma kallikrein system biomarkers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020144118A Division JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016536012A JP2016536012A (ja) | 2016-11-24 |
JP2016536012A5 true JP2016536012A5 (ja) | 2017-11-24 |
JP6757252B2 JP6757252B2 (ja) | 2020-09-16 |
Family
ID=52993413
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016549206A Active JP6757252B2 (ja) | 2013-10-21 | 2014-10-17 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
JP2022137393A Pending JP2022188017A (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020144118A Active JP7135039B2 (ja) | 2013-10-21 | 2020-08-28 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
JP2022137393A Pending JP2022188017A (ja) | 2013-10-21 | 2022-08-31 | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
Country Status (13)
Country | Link |
---|---|
US (2) | US11372002B2 (ja) |
EP (2) | EP3060582B1 (ja) |
JP (3) | JP6757252B2 (ja) |
KR (3) | KR102521947B1 (ja) |
CN (1) | CN105873951A (ja) |
AU (2) | AU2014340450B2 (ja) |
BR (1) | BR112016008970B1 (ja) |
CA (1) | CA2927824A1 (ja) |
DK (1) | DK3060582T3 (ja) |
ES (1) | ES2837858T3 (ja) |
IL (3) | IL289514B2 (ja) |
PL (1) | PL3060582T3 (ja) |
WO (1) | WO2015061183A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2948479T (pt) | 2013-01-20 | 2018-11-14 | Dyax Corp | Avaliação e tratamento de distúrbios mediados por bradicinina |
IL289514B2 (en) | 2013-10-21 | 2024-01-01 | Takeda Pharmaceuticals Co | Tests to determine system biomarkers for plasma kallikrein |
KR102665705B1 (ko) | 2013-10-21 | 2024-05-14 | 다케다 파머수티컬 컴패니 리미티드 | 자가면역 질환의 진단 및 치료 |
KR20230164767A (ko) * | 2015-03-30 | 2023-12-04 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
AU2016306653B2 (en) * | 2015-08-13 | 2021-05-13 | Takeda Pharmaceutical Company Limited | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation |
CN113655228A (zh) * | 2015-10-19 | 2021-11-16 | 武田药品工业株式会社 | 检测裂解的高分子量激肽原的免疫测定方法 |
AU2016372159B2 (en) | 2015-12-15 | 2022-03-24 | Takeda Pharmaceutical Company Limited | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK |
KR20230044024A (ko) * | 2016-09-16 | 2023-03-31 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
AU2017325999C1 (en) | 2016-09-16 | 2024-03-07 | Takeda Pharmaceutical Company Limited | RNA biomarkers for hereditary angioedema |
NZ751481A (en) * | 2016-09-16 | 2024-02-23 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
EP3521828A1 (en) * | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
US20200407771A1 (en) * | 2018-02-22 | 2020-12-31 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
CN111057745B (zh) * | 2019-12-30 | 2022-08-12 | 中国科学院生态环境研究中心 | 一种物质的血液毒性效应的高通量筛选方法 |
CN114166924A (zh) * | 2021-12-03 | 2022-03-11 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
WO2024003617A2 (en) * | 2022-06-30 | 2024-01-04 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JPS63185398A (ja) * | 1986-09-10 | 1988-07-30 | Nippon Zoki Pharmaceut Co Ltd | 生理活性物質測定法 |
US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
AU2548992A (en) | 1991-08-13 | 1993-03-16 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
JP3805785B2 (ja) | 1994-01-11 | 2006-08-09 | ダイアックス コープ. | カリクレイン阻害クニッツドメイン蛋白質およびその相同体 |
JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第xii因子活性化法 |
US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
US6242210B1 (en) * | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Hcvコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
US7678541B2 (en) * | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
US6913900B2 (en) * | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
ES2559927T3 (es) | 2002-06-07 | 2016-02-16 | Dyax Corp. | Prevención y reducción de pérdida de sangre y respuesta inflamatoria |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
EP1598428A1 (en) * | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
DK1981519T3 (en) | 2005-12-29 | 2018-02-19 | Dyax Corp | protease inhibition |
US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
CA2696208A1 (en) | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
EP2215256A1 (en) | 2007-10-22 | 2010-08-11 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
US20110160434A1 (en) | 2008-07-07 | 2011-06-30 | Nippon Zoki Pharmaceutical Co., Ltd. | Fibromyalgia test method |
US20110212104A1 (en) | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
EP2369930A4 (en) * | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE FROM PLASMA CALLICINE INHIBITORS |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
WO2011075684A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
SI2521568T1 (sl) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
WO2012009447A2 (en) | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
WO2012075407A2 (en) | 2010-12-02 | 2012-06-07 | Becton, Dickinson And Company | Blood collection devices containing blood stabilization agent |
CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
EP3320922A1 (en) | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
PT2948479T (pt) | 2013-01-20 | 2018-11-14 | Dyax Corp | Avaliação e tratamento de distúrbios mediados por bradicinina |
CA2899594A1 (en) | 2013-02-01 | 2014-08-07 | Keith A. Moskowitz | Blood collection devices containing contact pathway inhibition additives |
KR102665705B1 (ko) | 2013-10-21 | 2024-05-14 | 다케다 파머수티컬 컴패니 리미티드 | 자가면역 질환의 진단 및 치료 |
IL289514B2 (en) | 2013-10-21 | 2024-01-01 | Takeda Pharmaceuticals Co | Tests to determine system biomarkers for plasma kallikrein |
KR102424183B1 (ko) | 2014-01-21 | 2022-07-26 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
CN113655228A (zh) | 2015-10-19 | 2021-11-16 | 武田药品工业株式会社 | 检测裂解的高分子量激肽原的免疫测定方法 |
-
2014
- 2014-10-17 IL IL289514A patent/IL289514B2/en unknown
- 2014-10-17 AU AU2014340450A patent/AU2014340450B2/en active Active
- 2014-10-17 CN CN201480070281.6A patent/CN105873951A/zh active Pending
- 2014-10-17 PL PL14856778T patent/PL3060582T3/pl unknown
- 2014-10-17 DK DK14856778.7T patent/DK3060582T3/da active
- 2014-10-17 KR KR1020227027698A patent/KR102521947B1/ko active IP Right Grant
- 2014-10-17 KR KR1020167013432A patent/KR102432826B1/ko active IP Right Grant
- 2014-10-17 WO PCT/US2014/061247 patent/WO2015061183A1/en active Application Filing
- 2014-10-17 CA CA2927824A patent/CA2927824A1/en active Pending
- 2014-10-17 KR KR1020237012295A patent/KR20230054745A/ko not_active Application Discontinuation
- 2014-10-17 EP EP14856778.7A patent/EP3060582B1/en active Active
- 2014-10-17 EP EP20197583.6A patent/EP3808857A1/en active Pending
- 2014-10-17 ES ES14856778T patent/ES2837858T3/es active Active
- 2014-10-17 BR BR112016008970-7A patent/BR112016008970B1/pt active IP Right Grant
- 2014-10-17 JP JP2016549206A patent/JP6757252B2/ja active Active
- 2014-10-17 US US15/030,811 patent/US11372002B2/en active Active
-
2016
- 2016-04-19 IL IL245205A patent/IL245205B/en active IP Right Grant
-
2020
- 2020-04-19 IL IL274055A patent/IL274055B/en unknown
- 2020-08-10 AU AU2020217316A patent/AU2020217316B2/en active Active
- 2020-08-28 JP JP2020144118A patent/JP7135039B2/ja active Active
-
2021
- 2021-12-20 US US17/555,636 patent/US20220291232A1/en active Pending
-
2022
- 2022-08-31 JP JP2022137393A patent/JP2022188017A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016536012A5 (ja) | ||
Halvorsen et al. | Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab | |
Posch et al. | C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2–infected primary human airway epithelia | |
Qin et al. | A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis | |
Li et al. | Circulating microRNAs as potential biomarkers for coronary plaque rupture | |
JP2017524130A5 (ja) | ||
WO2014140933A8 (en) | Method for the prognosis and treatment of cancer metastasis | |
CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
JP2017503488A5 (ja) | ||
JP2016511823A5 (ja) | ||
Li et al. | MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression | |
JP2008537474A5 (ja) | ||
Wang et al. | Circulating exosomes and exosomal lncRNA HIF1A-AS1 in atherosclerosis | |
JP2017500584A5 (ja) | ||
Brooks et al. | The gut microbiome: a missing link in understanding the gastrointestinal manifestations of COVID-19? | |
US10895572B2 (en) | Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients | |
Kovalenko et al. | ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age | |
JP2017514813A5 (ja) | ||
Song et al. | Caspase-3 is a target gene of c-Jun: ATF2 heterodimers during apoptosis induced by activity deprivation in cerebellar granule neurons | |
JP7463351B2 (ja) | 脳卒中の血液バイオマーカー | |
AU2018275891A1 (en) | Articles of manufacture and methods related to toxicity associated with cell therapy | |
Solheim et al. | Prothrombotic markers in patients with acute myocardial infarction and left ventricular thrombus formation treated with pci and dual antiplatelet therapy | |
Shen et al. | Screening of differentially expressed genes related to severe sepsis induced by multiple trauma with DNA microarray. | |
Zhang et al. | Diagnostic value of circulating microRNA‐19b in heart failure | |
Gutiérrez-Chamorro et al. | SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients |